Geode Capital Management
VIR icon

Geode Capital Management’s Vir Biotechnology VIR Stock Holding History

Geode Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.1M Buy
3,348,366
+690,523
+26% +$6.57M ﹤0.01% 1841
2026
Q1 		$23.8M Buy
2,657,843
+329,636
+14% +$2.63M ﹤0.01% 1911
2025
Q4 		$14M Buy
2,328,207
+81,985
+4% +$488K ﹤0.01% 2210
2025
Q3 		$12.8M Sell
2,246,222
-6,198
-0.3% -$31.7K ﹤0.01% 2264
2025
Q2 		$11.4M Sell
2,252,420
-42,611
-2% -$228K ﹤0.01% 2276
2025
Q1 		$14.9M Buy
2,295,031
+98,430
+4% +$875K ﹤0.01% 2062
2024
Q4 		$16.1M Buy
2,196,601
+7,827
+0.4% +$61.7K ﹤0.01% 2073
2024
Q3 		$16.4M Buy
2,188,774
+5,146
+0.2% +$44.7K ﹤0.01% 2088
2024
Q2 		$19.4M Buy
2,183,628
+234,439
+12% +$2.25M ﹤0.01% 1939
2024
Q1 		$19.7M Buy
1,949,189
+62,793
+3% +$640K ﹤0.01% 1937
2023
Q4 		$19M Buy
1,886,396
+92,532
+5% +$846K ﹤0.01% 1954
2023
Q3 		$16.8M Buy
1,793,864
+103,087
+6% +$1.47M ﹤0.01% 1939
2023
Q2 		$41.5M Buy
1,690,777
+165,359
+11% +$4.15M ﹤0.01% 1379
2023
Q1 		$35.5M Buy
1,525,418
+59,140
+4% +$1.51M ﹤0.01% 1426
2022
Q4 		$37.1M Buy
1,466,278
+50,049
+4% +$1.23M 0.01% 1357
2022
Q3 		$27.3M Buy
1,416,229
+37,360
+3% +$950K ﹤0.01% 1520
2022
Q2 		$35.1M Buy
1,378,869
+133,478
+11% +$3.12M 0.01% 1360
2022
Q1 		$32M Buy
1,245,391
+13,571
+1% +$403K ﹤0.01% 1568
2021
Q4 		$51.6M Buy
1,231,820
+36,062
+3% +$1.41M 0.01% 1286
2021
Q3 		$52M Buy
1,195,758
+28,418
+2% +$1.23M 0.01% 1240
2021
Q2 		$55.2M Buy
1,167,340
+89,918
+8% +$4.09M 0.01% 1216
2021
Q1 		$55.2M Buy
1,077,422
+111,047
+11% +$5.98M 0.01% 1147
2020
Q4 		$25.9M Buy
966,375
+52,065
+6% +$1.69M ﹤0.01% 1552
2020
Q3 		$31.4M Buy
914,310
+524,887
+135% +$22.6M 0.01% 1192
2020
Q2 		$16M Buy
389,423
+273,143
+235% +$9.17M ﹤0.01% 1653
2020
Q1 		$3.98M Buy
116,280
+81,001
+230% +$2.18M ﹤0.01% 2271
2019
Q4 		$443K Buy
+35,279
New +$473K ﹤0.01% 3541

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Geode Capital Management's VIR Position: Q2 2026 in Review

Geode Capital Management increased its Vir Biotechnology (VIR) stake by 26% in Q2 2026, buying an estimated $6.57M and bringing the position to 3,348,366 shares worth $34.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1841.

Geode Capital Management first reported a position in VIR in Q4 2019 and has held it in 27 quarters since. The position peaked at $55.2M in Q1 2021. 222 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Geode Capital Management held 3,348,366 shares of Vir Biotechnology worth $34.1M as of Q2 2026.
  • Geode Capital Management bought 690,523 Vir Biotechnology shares in Q2 2026, an estimated $6.57M.
  • Vir Biotechnology made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #1841 holding.
  • Geode Capital Management first reported a position in Vir Biotechnology in Q4 2019 and has held it in 27 quarters since.
  • Geode Capital Management's Vir Biotechnology position peaked at $55.2M in Q1 2021.
  • 222 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.